Gender | High risk of Breast Carcinoma
Item
women at high risk for breast cancer, defined as any of the following groups:
boolean
C0079399 (UMLS CUI [1])
C0332167 (UMLS CUI [2,1])
C0678222 (UMLS CUI [2,2])
Gail Risk Model Percentage
Item
five year gail risk > 1.7%
boolean
C1511297 (UMLS CUI [1,1])
C0439165 (UMLS CUI [1,2])
BRCA1 Mutation Carrier | BRCA2 Mutation Carrier
Item
known brca1/brca2 mutation carrier
boolean
C3899965 (UMLS CUI [1])
C3899964 (UMLS CUI [2])
Family history Consistent with Hereditary Breast Cancer
Item
family history consistent with hereditary breast cancer
boolean
C0241889 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C0346153 (UMLS CUI [1,3])
Atypical hyperplasia | Lobular carcinoma in situ of breast
Item
prior biopsy exhibiting atypical hyperplasia or lobular carcinoma in situ (lcis)
boolean
C0333977 (UMLS CUI [1])
C0279563 (UMLS CUI [2])
Invasive carcinoma of breast | DCIS | Standard therapy Completed | Tamoxifen | Aromatase Inhibitors | Tamoxifen Absent | Aromatase Inhibitors Absent
Item
history of invasive breast cancer or ductal carcinoma in situ (dcis) and have completed standard therapy including tamoxifen/aromatase inhibitor or will not be treated with tamoxifen/aromatase inhibitor
boolean
C0853879 (UMLS CUI [1])
C0007124 (UMLS CUI [2])
C2936643 (UMLS CUI [3,1])
C0205197 (UMLS CUI [3,2])
C0039286 (UMLS CUI [4])
C0593802 (UMLS CUI [5])
C0039286 (UMLS CUI [6,1])
C0332197 (UMLS CUI [6,2])
C0593802 (UMLS CUI [7,1])
C0332197 (UMLS CUI [7,2])
Informed Consent
Item
signed informed consent
boolean
C0021430 (UMLS CUI [1])
Secondary malignant neoplasm of female breast
Item
metastatic breast cancer
boolean
C0346993 (UMLS CUI [1])
Therapeutic procedure | Chemotherapy | Therapeutic radiology procedure | SERMs
Item
undergoing treatment (chemotherapy, radiation, or serms)
boolean
C0087111 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C1522449 (UMLS CUI [3])
C0732611 (UMLS CUI [4])
Pregnancy | Breast Feeding | Pregnancy, Planned
Item
pregnancy or breast-feeding, or planning to become pregnant within one year prior to study entry
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
Soy Consumer Regular | Soy Food | Soy Supplements | Soy product
Item
regular soy consumers (i.e., < once per week of soy food, soy supplements or other products)
boolean
C0037733 (UMLS CUI [1,1])
C1707496 (UMLS CUI [1,2])
C0205272 (UMLS CUI [1,3])
C1258091 (UMLS CUI [2])
C0037733 (UMLS CUI [3,1])
C0242295 (UMLS CUI [3,2])
C1532456 (UMLS CUI [4])
Food Allergy | Allergy to soy | Nut Hypersensitivity
Item
known food allergies such as to soy or nuts
boolean
C0016470 (UMLS CUI [1])
C4075590 (UMLS CUI [2])
C0577620 (UMLS CUI [3])
Avoidance Soy Foods Unwilling | Avoidance Soy Supplements Unwilling
Item
not willing to avoid soy foods/supplements during study period
boolean
C0870186 (UMLS CUI [1,1])
C1258091 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
C0870186 (UMLS CUI [2,1])
C0037733 (UMLS CUI [2,2])
C0242295 (UMLS CUI [2,3])
C0558080 (UMLS CUI [2,4])
Use of Exogenous hormones | Use of Oral Contraceptives | Use of Exogenous hormones Planned
Item
current users of exogenous hormones or oral contraceptive or planning to use exogenous hormones during the duration of the study
boolean
C1524063 (UMLS CUI [1,1])
C0450231 (UMLS CUI [1,2])
C1524063 (UMLS CUI [2,1])
C0009905 (UMLS CUI [2,2])
C1524063 (UMLS CUI [3,1])
C0450231 (UMLS CUI [3,2])
C1301732 (UMLS CUI [3,3])
Aspirin Discontinue Unable | NSAIDs Discontinue Unable
Item
cannot stop taking aspirin or nsaids within a week of breast biopsy
boolean
C0004057 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
C0003211 (UMLS CUI [2,1])
C1444662 (UMLS CUI [2,2])
C1299582 (UMLS CUI [2,3])
Study Subject Participation Status
Item
active participant in other ongoing trials
boolean
C2348568 (UMLS CUI [1])